Interestingly, something similar has been observed in AD, whereby clusterin trafficking has been altered by both Aβ treatment (Killick et al., 2014) and CLU AD-mutations (Bettens et al., 2015), resulting in increased intracellular clusterin and a reduction in secreted clusterin. Here, CLU is linked to Alzheimer disease.